Alfentanil (CED0004038)

Record Information

Version

1.0

Creation Date

2009-07-21 20:27:40 UTC

Update Date

2026-05-14 16:49:23 UTC

SynCED ID

CED0004038

Secondary Accession Numbers

CHEM002275
T3D2894

Identification

Common Name

Alfentanil

Class

Small Molecule

Description

Alfentanil is an exogenous organic compound with the formula C21H32N6O3 and an average molecular weight of 416.52 g/mol. At room temperature, it exists as a solid. Alfentanil belongs to the anilides, a subclass of benzene and substituted derivatives within the organic compounds. This compound functions as an intravenous anaesthetic, a central nervous system depressant, a peripheral nervous system drug, and an opioid analgesic. Biologically, it acts as a mu-opioid receptor agonist. Its recorded protein targets include the mu-type opioid receptor (OPRM1), the kappa-type opioid receptor (OPRK1), alpha-1-acid glycoprotein 1 (ORM1), albumin (ALB), and ATP-dependent translocase ABCB1. Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase, subsequently affecting the release of nociceptive neurotransmitter. Alfentanil is found in eight recorded sources, including anesthetics within healthcare, pharmaceuticals, and veterinary products. Other recorded sources include household cleaning and consumer products such as bleaching agents, cigar cigarettes, non-electric simulated smoking devices, and tobacco product cases, as well as electrical and electronic equipment such as antennas, electric switches, and electrically stimulated smoking devices. The recorded route of exposure for this compound is intravenous.

Contaminant Type

Amide
Amine
Analgesic
Analgesic, Opioid
Anesthetic
Anesthetic, Intravenous
Drug
Ether
Metabolite
Narcotic
Opiate Agonist
Organic Compound
Synthetic Compound

Chemical Structure

MOL SDF PDB SMILES InChI

Synonyms

Value	Source
Alfentanilum	ChEBI
Alfentanyl	ChEBI
N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide	ChEBI
Rapifen	Kegg
Esteve brand OF alfentanil hydrochloride	HMDB
Fanaxal	HMDB
ICI brand OF alfentanil hydrochloride	HMDB
Janssen brand OF alfentanil hydrochloride	HMDB
Limifen	HMDB
Alfenta	HMDB
Alfentanil hydrochloride	HMDB

Chemical Formula

C₂₁H₃₂N₆O₃

Average Molecular Mass

416.517 g/mol

Monoisotopic Mass

416.254 g/mol

CAS Registry Number

71195-58-9

IUPAC Name

N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-1,2,3,4-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide

Traditional Name

alfentanil

SMILES

CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O

InChI Identifier

InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3

InChI Key

IDBPHNDTYPBSNI-UHFFFAOYSA-N

Chemical Taxonomy

Description

Belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.

Kingdom

Organic compounds

Super Class

Benzenoids

Class

Benzene and substituted derivatives

Sub Class

Anilides

Direct Parent

Anilides

Alternative Parents

Substituents

Anilide
Piperidine
Azole
Heteroaromatic compound
Tertiary carboxylic acid amide
Tetrazole
Amino acid or derivatives
Carboxamide group
Tertiary amine
Tertiary aliphatic amine
Carboxylic acid derivative
Dialkyl ether
Ether
Azacycle
Organoheterocyclic compound
Organonitrogen compound
Organic nitrogen compound
Amine
Organopnictogen compound
Organooxygen compound
Organic oxide
Hydrocarbon derivative
Organic oxygen compound
Carbonyl group
Aromatic heteromonocyclic compound

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

piperidines (CHEBI:2569 )
monocarboxylic acid amide (CHEBI:2569 )

Biological Properties

Status

Detected and Not Quantified

Origin

Exogenous

Cellular Locations

Extracellular
Membrane

Biofluid Locations

Not Available

Tissue Locations

Not Available

Applications

Biological Roles

Chemical Roles

Not Available

Organoleptic Effects

Not Available

Physical Properties

State

Solid

Appearance

White powder.

Experimental Properties

Property	Value
Melting Point	140.8°C
Boiling Point	Not Available
Solubility	34.6 mg/L

Predicted Properties

Property	Value	Source
Water Solubility	0.25 g/L	ALOGPS
logP	2.2	ALOGPS
logP	2.81	ChemAxon
logS	-3.2	ALOGPS
pKa (Strongest Basic)	7.5	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	6	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	81.05 Å²	ChemAxon
Rotatable Bond Count	9	ChemAxon
Refractivity	118.59 m³·mol⁻¹	ChemAxon
Polarizability	45.57 Å³	ChemAxon
Number of Rings	3	ChemAxon
Bioavailability	Yes	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Spectra

Spectrum Type	Description	Splash Key	Deposition Date	View
Predicted GC-MS	Predicted GC-MS Spectrum	splash10-0aps-5759000000-11ce8f647981a86e2993	Not Available	View Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum	Not Available	Not Available	View Spectrum
Predicted GC-MS	Predicted GC-MS Spectrum	Not Available	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-014i-0000900000-a802cc961dad7c6326a5	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-014i-0395300000-498fafc6962b6fd82e9c	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-00kb-0912000000-43c2343a5fa4997ca93a	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-015a-2900000000-16b845b2c742175e38cd	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-015a-7900000000-e9bd243460dd40507619	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-015a-2900000000-16b845b2c742175e38cd	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-015a-7900000000-e9bd243460dd40507619	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-00kb-0912000000-43c2343a5fa4997ca93a	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-00kb-0912000000-b5e89d86b302adb65517	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-015a-2900000000-d76f968c16c60e097fbc	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-014i-0395300000-498fafc6962b6fd82e9c	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-014i-0000900000-a802cc961dad7c6326a5	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-015a-7900000000-7fdf62ef447e7c6e19fa	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-00kb-0912000000-1f6c2333f39ce390e20e	Not Available	View Spectrum
LC-MS/MS	LC-MS/MS Spectrum	splash10-015a-7900000000-1c558c3f776664f15eb1	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-00di-9007000000-cbc10f94b61327a4ec79	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0006-9022000000-5dee7e8e9ca18ed6afa7	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0006-9052000000-d1f0fa6385e6848912c6	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0cdr-6509300000-1d06eb64c3c9a376ea43	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0a4i-3109000000-3960d2bbff65d1a0ecc0	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0btc-9423000000-8194ccf6d27ec2cb2870	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-014i-0000900000-1e0b9eadc3dc511d87d7	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-014i-0392100000-333cd54e08c49ae75cde	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0296-1936000000-2f1acf618b9904cbaffe	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-014i-0009300000-f5e9f9e4f40759f2ff43	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-014m-4419000000-eeccac83603b2a57368f	Not Available	View Spectrum
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum	splash10-0gw3-3197000000-dd1a31bf474dbccd9255	Not Available	View Spectrum

Toxicity Profile

Toxicity Values

Toxicity Value	Organism	Dose Descriptor	Route of Exposure	Predicted or Experimental	Toxicity Rating	Reference
707.0 Log mg/kg [400:1300]	Rat	LD50	oral	predicted	Not Available	Not Available

Toxicity / Toxin Class

Not Available

Mechanism of Toxicity

Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Alfentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.

Carcinogenicity (IARC Classification)

No indication of carcinogenicity to humans (not listed by IARC).

Minimum Risk Level

Not Available

Symptoms

Symptoms of overexposure include characteristic rigidity of the skeletal muscles, cardiac and respiratory depression, and narrowing of the pupils.

Treatment

Intravenous administration of an opioid antagonist such as naloxone should be employed as a specific antidote to manage respiratory depression. The duration of respiratory depression following overdosage with ALFENTA may be longer than the duration of action of the opioid antagonist. Administration of an opioid antagonist should not preclude immediate establishment of a patent airway, administration of oxygen, and assisted or controlled ventilation as indicated for hypoventilation or apnea. If respiratory depression is associated with muscular rigidity, a neuromuscular blocking agent may be required to facilitate assisted or controlled ventilation. Intravenous fluids and vasoactive agents may be required to manage hemodynamic instability. (2)

Health Effects

Health Effect	Relationship	Direction	Description	Reference
delirium	Associated With?	decrease	A disorder characterized by the acute and sudden development of confusion, illusions, movement changes, inattentiveness, agitation, and hallucinations. Usually, it is a reversible condition. (NCI CTCAE)	PMC12985773
Anesthesia	Not Available	Not Available	Not Available	PMC5725546
Deep Sedation	Not Available	Not Available	Not Available	PMC3607964
Emergence Delirium	Has Therapeutic Effect On	Not Available	Not Available	PMC12985773
Emergence Delirium	Associated With?	decrease	Not Available	PMC12985773

Exposure Sources

Source ID	Source	Sector	Reference
CEDs000010	Insecticides?Insecticides are synthetic chemicals designed to control or eliminate insect pests that threaten crops and other agricultural products.	Agriculture & land management	PubChem
CEDs000369	Anesthetics?Anesthetics are synthetic chemicals used to induce loss of sensation or consciousness in patients undergoing medical procedures.	Healthcare, pharmaceuticals & veterinary products	Not Available
CEDs000479	Effluent?Effluent refers to liquid waste or sewage that is discharged into the environment, typically resulting from industrial processes, municipal wastewater treatment, or agricultural runoff.	Wastewater, sanitation & biosolids	PMC12065065
CEDs000506	Antennas?Antennas, commonly used in communication technologies, can be a source of synthetic chemical contamination through the materials and coatings used in their construction.	Electrical & Electronic Equipment	PubChem
CEDs000511	Conductors Or Conductive Bodies Characterised By The Conductive Materials?Conductors, or conductive bodies, are materials that allow the flow of electrical current, typically made from metals such as copper, aluminum, or silver.	Electrical & Electronic Equipment	PubChem
CEDs000517	Electric Switches?Electric switches, integral components in numerous devices, can be a source of synthetic chemical contamination due to the materials and manufacturing processes involved in their production.	Electrical & Electronic Equipment	PubChem
CEDs000518	Electrically Stimulated Smoking Devices?Electrically stimulated smoking devices, commonly known as e-cigarettes or vape pens, utilize electrical components to heat a liquid solution, often containing nicotine, flavorings, and other additives, to produce an aerosol for inhalation.	Electrical & Electronic Equipment	PubChem
CEDs000545	Food Preservation?Food preservation often involves the use of synthetic chemicals, such as preservatives, flavor enhancers, and color additives, to extend shelf life and enhance the sensory qualities of food products.	Food, food processing & cookware	PubChem
CEDs000555	Bleaching Agents?Bleaching agents are chemical substances used to whiten or lighten materials, often employed in various cleaning products for their stain removal and disinfecting properties.	Household cleaning & consumer products	PubChem
CEDs000556	Cigar Cigarettes?Cigar cigarettes are a source of synthetic chemical contamination due to the combustion of various tobacco blends and additives.	Household cleaning & consumer products	PubChem
CEDs000559	Non Electric Simulated Smoking Devices?Non-electric simulated smoking devices, often designed to mimic the experience of smoking without combustion, can be sources of synthetic chemical contamination due to the materials and chemicals used in their construction and operation.	Household cleaning & consumer products	PubChem
CEDs000561	Perfumes Within Detergents And Soaps?Perfumes within detergents and soaps are synthetic fragrance compounds added to enhance the sensory experience of cleaning products.	Household cleaning & consumer products	PubChem
CEDs000567	Tobacco Product Cases?Tobacco product cases can serve as a source of synthetic chemical contamination due to the presence of various additives and chemicals used in tobacco processing and product manufacturing.	Household cleaning & consumer products	PubChem
CEDs000569	Tobacco Smoke Filters?Tobacco smoke filters are designed to reduce the inhalation of harmful substances in cigarette smoke, including tar and other particulate matter.	Household cleaning & consumer products	PubChem
CEDs000580	Manufacture Preparation Of Tobacco Products?The manufacture and preparation of tobacco products involve various processes that can result in the introduction of synthetic chemicals into the environment.	Industrial manufacturing & chemical processing	PubChem
CEDs000581	Paper Making Machines?Paper making machines utilize various synthetic chemicals throughout the production process, including additives, coatings, and bleaching agents.	Industrial manufacturing & chemical processing	PubChem
CEDs000596	Acaricides?Acaricides are synthetic chemicals specifically designed to target and control mite populations that can damage crops and plants.	Agriculture & land management	PubChem
CEDs000605	Pest Repellants?Pest repellents, often formulated from synthetic chemicals, are widely used to protect crops from insect infestations and other pests.	Agriculture & land management	PubChem
CEDs000610	Aftersun Products?Aftersun products are designed to soothe and hydrate the skin after sun exposure, often containing various synthetic chemicals such as emollients, preservatives, and fragrances.	Personal care & cosmetics	PubChem
CEDs000611	Anti Perspirants Or Body Deoderants?Antiperspirants and body deodorants commonly contain synthetic chemicals such as aluminum compounds, parabens, and synthetic fragrances.	Personal care & cosmetics	PubChem
CEDs000614	Essential Oils Or Perfumes?Essential oils and perfumes are complex mixtures of volatile compounds derived from natural or synthetic sources, commonly used for their aromatic properties.	Personal care & cosmetics	PubChem
CEDs000650	Purses Luggage Hand Bags?Purses, luggage, and handbags are often manufactured using synthetic materials such as polyvinyl chloride (PVC), polyurethane, and various types of nylon.	Textiles, leather & furnishings	PubChem
CEDs000651	Purses Money Bags Wallets?Purses, money bags, and wallets are often manufactured using synthetic materials, including plastics, polyurethanes, and various treated fabrics.	Textiles, leather & furnishings	PubChem
CEDs000671	Airplanes And Helicopters?Airplanes and helicopters are significant sources of synthetic chemical contamination primarily through the use of aviation fuels, lubricants, and de-icing agents.	Aviation & Aerospace	PubChem
CEDs000685	Ceramics?Ceramics can be a source of synthetic chemical contamination through various additives and processing agents used in their production.	Building & Construction	PubChem
CEDs000696	Nanotechnology?Nanotechnology involves the manipulation of materials at the molecular or atomic level, typically within the range of 1 to 100 nanometers.	Industrial manufacturing & chemical processing	PubChem
CEDs000735	Explosives?Explosives are chemical compounds or mixtures designed to undergo rapid decomposition, releasing energy in the form of gas and heat.	Defense & military infrastructure	PubChem
CEDs000740	Paper?Paper production involves the processing of wood fibers and the use of various chemicals, which can lead to synthetic chemical contamination.	Paper, pulp & fiber products	PubChem
CEDs000744	Water, Wastewater, & Sewage Treatment?Water, wastewater, and sewage treatment processes are critical for managing and mitigating pollutants in water systems.	Wastewater, sanitation & biosolids	PubChem

Pathways

4 pathwaysPathway Source: PathBank

Alfentanil Action Pathway

Alfentanil Opioid Agonist Action Pathway

Alfentanil Metabolism Pathway

Alfentanil Drug Metabolism Action Pathway

Targets

Structure	Protein	UniProt ID	Organism	Relationship	Details
Click to view 3D structure	Cytochrome P450 3A4	P08684	Humans	Known	Not Available
Click to view 3D structure	Sigma non-opioid intracellular receptor 1	Q60492	Cavia porcellus	Predicted (SEA)	Prediction Confidence Score 0.518 Applicability Domain 1.0 Statistical Significance 0.0015 Supporting Reference Compounds 229 E-value 11.6774
Click to view 3D structure	Mu-type opioid receptor	P33535	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.512 Applicability Domain 1.0 Statistical Significance 0.0077 Supporting Reference Compounds 229 E-value 59.6325
Click to view 3D structure	Mu-type opioid receptor	P97266	Cavia porcellus	Predicted (SEA)	Prediction Confidence Score 0.434 Applicability Domain 1.0 Statistical Significance 0.015 Supporting Reference Compounds 186 E-value 116.54
Click to view 3D structure	Kappa-type opioid receptor	P41144	Cavia porcellus	Predicted (SEA)	Prediction Confidence Score 0.408 Applicability Domain 1.0 Statistical Significance 0.0161 Supporting Reference Compounds 199 E-value 125.415
Click to view 3D structure	Mu-type opioid receptor	P35372	Humans	Predicted (SEA)	Prediction Confidence Score 0.38 Applicability Domain 0.615 Statistical Significance 0.027 Supporting Reference Compounds 527 E-value 210.193
Click to view 3D structure	ATP-dependent translocase ABCB1	P08183	Humans	Predicted (SEA)	Prediction Confidence Score 0.345 Applicability Domain 0.615 Statistical Significance 0.0058 Supporting Reference Compounds 139 E-value 45.1525
Click to view 3D structure	Sigma non-opioid intracellular receptor 1	Q99720	Humans	Predicted (SEA)	Prediction Confidence Score 0.298 Applicability Domain 0.348 Statistical Significance 0.0658 Supporting Reference Compounds 562 E-value 512.481
Click to view 3D structure	Delta-type opioid receptor	P41143	Humans	Predicted (SEA)	Prediction Confidence Score 0.29 Applicability Domain 0.348 Statistical Significance 0.068 Supporting Reference Compounds 427 E-value 529.063
Click to view 3D structure	Kappa-type opioid receptor	P41145	Humans	Predicted (SEA)	Prediction Confidence Score 0.288 Applicability Domain 0.348 Statistical Significance 0.0811 Supporting Reference Compounds 532 E-value 631.435
Click to view 3D structure	Voltage-gated inwardly rectifying potassium channel KCNH2	Q12809	Humans	Predicted (SEA)	Prediction Confidence Score 0.284 Applicability Domain 0.348 Statistical Significance 0.2399 Supporting Reference Compounds 1498 E-value 1867.91
Click to view 3D structure	D(4) dopamine receptor	P21917	Humans	Predicted (SEA)	Prediction Confidence Score 0.282 Applicability Domain 0.348 Statistical Significance 0.0861 Supporting Reference Compounds 524 E-value 670.671
Click to view 3D structure	Alpha-1B adrenergic receptor	P35368	Humans	Predicted (SEA)	Prediction Confidence Score 0.278 Applicability Domain 0.348 Statistical Significance 0.0482 Supporting Reference Compounds 298 E-value 375.389
Click to view 3D structure	Alpha-1A adrenergic receptor	P35348	Humans	Predicted (SEA)	Prediction Confidence Score 0.278 Applicability Domain 0.348 Statistical Significance 0.0616 Supporting Reference Compounds 376 E-value 479.473
Click to view 3D structure	Sigma non-opioid intracellular receptor 1	Q9R0C9	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.275 Applicability Domain 0.348 Statistical Significance 0.0408 Supporting Reference Compounds 207 E-value 317.936
Click to view 3D structure	5-hydroxytryptamine receptor 2A	P28223	Humans	Predicted (SEA)	Prediction Confidence Score 0.266 Applicability Domain 0.286 Low confidence Statistical Significance 0.1887 Supporting Reference Compounds 955 E-value 1469.4
Click to view 3D structure	Alpha-1A adrenergic receptor	P43140	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.264 Applicability Domain 0.275 Low confidence Statistical Significance 0.0541 Supporting Reference Compounds 208 E-value 421.164
Click to view 3D structure	Sodium-dependent serotonin transporter	P31652	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.264 Applicability Domain 0.299 Low confidence Statistical Significance 0.0685 Supporting Reference Compounds 297 E-value 533.111
Click to view 3D structure	D(2) dopamine receptor	P14416	Humans	Predicted (SEA)	Prediction Confidence Score 0.263 Applicability Domain 0.275 Low confidence Statistical Significance 0.2143 Supporting Reference Compounds 1103 E-value 1668.46
Click to view 3D structure	D(3) dopamine receptor	P35462	Humans	Predicted (SEA)	Prediction Confidence Score 0.262 Applicability Domain 0.275 Low confidence Statistical Significance 0.1853 Supporting Reference Compounds 861 E-value 1442.39
Click to view 3D structure	5-hydroxytryptamine receptor 1A	P19327	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.262 Applicability Domain 0.268 Low confidence Statistical Significance 0.1355 Supporting Reference Compounds 541 E-value 1055.17
Click to view 3D structure	5-hydroxytryptamine receptor 7	P34969	Humans	Predicted (SEA)	Prediction Confidence Score 0.261 Applicability Domain 0.286 Low confidence Statistical Significance 0.1344 Supporting Reference Compounds 565 E-value 1046.45
Click to view 3D structure	D(2) dopamine receptor	P61169	Rat	Predicted (SEA)	Prediction Confidence Score 0.261 Applicability Domain 0.275 Low confidence Statistical Significance 0.1306 Supporting Reference Compounds 528 E-value 1016.63
Click to view 3D structure	Delta-type opioid receptor	P33533	Rattus norvegicus	Predicted (SEA)	Prediction Confidence Score 0.26 Applicability Domain 0.348 Statistical Significance 0.063 Supporting Reference Compounds 164 E-value 490.684
Click to view 3D structure	Nociceptin receptor	P41146	Humans	Predicted (SEA)	Prediction Confidence Score 0.26 Applicability Domain 0.348 Statistical Significance 0.0417 Supporting Reference Compounds 73 E-value 324.32
Click to view 3D structure	5-hydroxytryptamine receptor 2B	P41595	Humans	Predicted (SEA)	Prediction Confidence Score 0.259 Applicability Domain 0.266 Low confidence Statistical Significance 0.1738 Supporting Reference Compounds 686 E-value 1352.71
Click to view 3D structure	Cytochrome P450 3A7	P24462	Humans	Known	Not Available
Click to view 3D structure	Mu-type opioid receptor	P35372	Humans	Known	Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Alfentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
Click to view 3D structure	Alpha-1-acid glycoprotein 1	P02763	Humans	Known	Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Alfentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
Click to view 3D structure	Cytochrome P450 3A5	P20815	Humans	Known	Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Alfentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
Click to view 3D structure	Albumin	P02768	Humans	Known	Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Alfentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
Click to view 3D structure	ATP-dependent translocase ABCB1	P08183	Humans	Known	Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Alfentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
Click to view 3D structure	Kappa-type opioid receptor	P41145	Humans	Known	Not Available

Concentrations

Not Available

External Links

DrugBank ID

DB00802

HMDB ID

HMDB0014940

FooDB ID

Not Available

Phenol Explorer ID

Not Available

KNApSAcK ID

Not Available

BiGG ID

Not Available

BioCyc ID

Not Available

METLIN ID

Not Available

PDB ID

Not Available

Wikipedia Link

Chemspider ID

ChEBI ID

PubChem Compound ID

Kegg Compound ID

YMDB ID

Not Available

ECMDB ID

Not Available

References

Synthesis Reference

Jacob Mathew, J. Killgore, “New methods for the synthesis of alfentanil, sufentanil, and remifentanil.” U.S. Patent US20060149071, issued July 06, 2006.

MSDS

Link

General References

Drugs.com http://www.drugs.com/cons/Alfenta.html
RxList: The Internet Drug Index (2009). http://www.rxlist.com/

Alfentanil (CED0004038)

Structure for CHEM002275: Alfentanil

Structure